Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment
⭐️no new onset IBD or exacerbation of IBD
⭐️no uveitis, infections, TB
Abs#1342
#ACR21
@RheumNow
https://t.co/x3OmLgInV0
Links:
Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Am…
https://bit.ly/30dsXl7
08-11-2021